CYMEVENE FOR INJECTION 500 MG

BSP PHARMACEUTICALS S.P.A. (DP + PRIMARY PACKAGER) - ITALYVALDEPHARM (DP + PRIMARY PACKAGER) (FRANCE)🇸🇬 Health Sciences Authority

Approval Date: Sep 6, 1990
Approval ID: 9f728d61cbf51649
Company: BSP PHARMACEUTICALS S.P.A. (DP + PRIMARY PACKAGER) - ITALYVALDEPHARM (DP + PRIMARY PACKAGER) (FRANCE)
Type: Therapeutic

Approval Details

Approval Id: 9f728d61cbf51649
Drug Name: CYMEVENE FOR INJECTION 500 MG
Product Name: CYMEVENE FOR INJECTION 500 MG
Approval Number: SIN05051P
Approval Date: 1990-09-06
Registrant: DKSH SINGAPORE PTE. LTD.
Licence Holder: DKSH SINGAPORE PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: INJECTION, POWDER, FOR SOLUTION
Dosage: 2.2. DOSAGE AND ADMINISTRATION General Cymevene must be reconstituted and diluted under the supervision of a healthcare professional and administered as an intravenous infusion (see section 4.2 Special Instructions for Use, Handling and Disposal – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a plastic cannula, into a vein with adequate blood flow (intramuscular or subcutaneous injection may result in severe tissue irritation due to the high pH (~ 11) of ganciclovir solution). Do not administer by rapid or bolus IV injection because the resulting excessive plasma levels may increase the toxicity of Cymevene (see section 4.2 Special Instructions for Use, Handling and Disposal – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). The recommended dosage, frequency, or infusion rates should not be exceeded. STANDARD DOSAGE FOR TREATMENT OF CMV DISEASE Dosage for patients with normal renal function Induction treatment: 5 mg/kg given as an IV infusion over one hour, every 12 hours for 14–21 days. Maintenance treatment: For immunocompromised patients at risk of relapse maintenance therapy may be given. 5 mg/kg given as an IV infusion over one hour, once daily on 7 days per week or 6 mg/kg once daily on 5 days per week. The duration of maintenance treatment should be determined on an individual basis. STANDARD DOSAGE FOR PREVENTION OF CMV DISEASE USING PRE-EMPTIVE THERAPY Dosage for patients with normal renal function Induction treatment: 5 mg/kg given as an IV infusion over one hour, every 12 hours for 7–14 days. Maintenance treatment: 5 mg/kg given as an IV infusion over one hour, once daily on 7 days per week or 6 mg/kg once daily on 5 days per week. The duration of maintenance treatment is based on the risk of CMV disease and should be determined on an individual basis. 2.2.1. Special dosage instructions Pediatric Patients Safety and efficacy of ganciclovir in pediatrics have not been established, including use for the treatment of congenital or neonatal CMV infections. The use of Cymevene in children warrants extreme caution due to the potential for long-term carcinogenicity and reproductive toxicity. The benefits of treatment should outweigh the risks (see section 3.2.5 Pharmacokinetics in Special Populations, Pediatric Population – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Geriatric patients No studies have been conducted in adults older than 65 years of age. Since renal clearance decreases with age, Cymevene should be administered to geriatric patients with special consideration of their renal status (see Table 1 and section 3.2.5 Pharmacokinetics in Special Populations, Geriatric population – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Renal impairment For patients with renal impairment, the dose of Cymevene should be modified as shown in the table below. <img src="/TGIF/Cymevene-Table1_281221.png" alt="Cymevene Dosage Table 1" /> Estimated creatinine clearance can be related to serum creatinine by the following formulae: <img src="/TGIF/Cymevene-Formula1_281221.png" alt="Cymevene Formula 1" /> As dosage modifications are recommended in patients with renal impairment, serum creatinine or estimated creatinine-clearance levels should be monitored carefully. Hepatic impairment The safety and efficacy of Cymevene have not been studied in patients with hepatic impairment (see section 3.2.5 Pharmacokinetics in Special Populations, Hepatic impairment – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Route Of Administration: INTRAVENOUS
Indication Info: 2.1. THERAPEUTIC INDICATION(S) Cymevene vials are indicated for the prevention and treatment of life- or sight-threatening cytomegalovirus (CMV) disease in immunocompromised individuals. The benefits of Cymevene for CMV prevention in patients with HIV may be limited.
Contraindications: 2.3. CONTRAINDICATIONS Cymevene is contraindicated in patients with hypersensitivity to ganciclovir, valganciclovir or to any of the excipients.
Atc Code: J05AB06
Atc Item Name: ganciclovir
Pharma Manufacturer Name: DKSH SINGAPORE PTE. LTD.

Active Ingredients

GANCICLOVIR SODIUM EQV GANCICLOVIR

500 mg

GANCICLOVIR SODIUM EQV GANCICLOVIR

500 mg

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Sep 6, 1990

Approval ID

9f728d61cbf51649

Type

Therapeutic

Back to HSA Approvals